Skip to main content

Use of an automated ACTH assay for the diagnosis of pituitary and adrenal-related diseases.

Brossaud J, Bouton M, Gatta B, Tabarin A, Corcuff JB

Publication: Clin Biochem (2011) • Vol 44 • Page 1160-2PMID: 21704612View on PubMed

Purpose

The purpose of this paper was to compare the accuracy of Liaison assay with immunoradiometric assay(IRMA) for the diagnosis of pituitary and adrenal diseases based on adrenocorticotropic hormone (ACTH) in plasma.

Conclusion

There were no clinical discrepancies in ACTH levels between assays, but the Liaison assay was unable to quantify ACTH in 25% of normal specimens and was not adequate for the determination of ACTH dependency in Cushing's syndrome.

Studies (1)

Purpose

The purpose of this study was to determine the effect of assay type on the measurement of ACTH in plasma from healthy individuals, and patients with Cushing's syndrome, adrenal tumors, or adrenal insufficiency. Fresh plasma was analyzed by IRMA, and plasma frozen at -80 degrees C prior to analysis was used for the Liaison assay.

Summary of Findings

There were no clinical discrepancies in ACTH levels between assays, but there was significant analytical bias. Importantly, using the Liaison assay, ACTH levels were below the limit of quantification for 25% of specimens from normal individuals, but all specimens were above the limit of detection of the IRMA. The IRMA was better able to segregate patients with ACTH-independent and ACTH-dependent Cushing's syndrome, while the Liaison assay was adequate for classifying primary versus secondary adrenal insufficiency.

  • Biospecimens

    FluidPlasma
    FluidBlood
  • Preservation Types

    None (Fresh)
  • Diagnoses

    NeoplasticCarcinoma
    Neoplastic
    NeoplasticBenign
    Normal
    Other diagnoses
  • Platforms

    PeptideImmunoradiometric assay
    PeptideClinical chemistry/auto analyzer
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Adrenal insufficiency
    Cushing's disease
    Clinical chemistry/auto analyzer SpecificTechnology platform
    IRMA